CEI Today: I, Pencil premiere today, Europe v. US fiscal cliff, and EPA carbon regs
Thursday, November 15, 2012 at 08:16AM 
FISCAL CLIFF, EUROPE v. US - MATTHEW MELCHIORRE
USA Today: America must avoid Europe's toxic tax remedy
With America threatening to run off the "fiscal cliff" of tax increases and spending cuts on Jan. 1, it risks repeating the mistakes of Europe. The folly of "austerity" composed mainly of tax hikes with less in the way of spending reductions has driven the economies of the Old World into the
ground.
We're next unless Congress keeps Uncle Sam out of Americans' wallets and takes a chainsaw to Washington's budget.
> Read the full commentary on USAToday.com
> Interview Matthew Melchiorre
OFF-LABEL DRUG PROMOTION - HENRY I. MILLER & GREGORY CONKOHoover.org: Free Speech for Big Pharma
|
|
OBAMA WAR ON COAL - MARLO LEWIS
The 2012 elections ensure that President Obama’s “war on coal” will continue for at least two more years. The administration’s preferred M.O. has been for the EPA to “enact” anti-coal policies that Congress would reject if such measures were introduced as legislation and put to a vote.
Consequently, defenders of free-market energy are stuck playing defense and their main weapon now is litigation. This is a hard slog because courts usually defer to agency interpretations of the statutes they administer. But sometimes petitioners win. > View the article on Forbes.com |
|
WORLD PREMIERE TODAY!
The Competitive Enterprise Institute is proud to announce a new ambitious film project: an animated adaptation of I, Pencil by Leonard Read. |
|
|
CEI is a non-profit, non-partisan public policy group dedicated to the principles of free enterprise and limited government. For more information about CEI, please visit our website, cei.org, and blogs, Globalwarming.org and OpenMarket.org. Follow CEI on Twitter! Twitter.com/ceidotorg.
NH INSIDER | Comments Off |
CEI,
Carbon Caps,
EPA,
Fiscal Cliff,
Regulatory Actions,
Video 

One of the most important elements of medicine is also among the least well known: the ability of physicians to prescribe approved medicines for purposes not sanctioned by the Food and Drug Administration. These so called “off-label” uses are perfectly legal, and doctors rely on them extensively. But in a number of ways, regulators make it difficult for doctors to learn about and prescribe drugs off-label; one such way is a rule that forbids manufacturers from promoting such uses. That might change soon. Two federal courts are now considering lawsuits that challenge the constitutionality of the off-label promotion ban.